Navigation Links
Associates of Cape Cod (ACC) and MDS Analytical Technologies Collaborate to Offer a More Robust LAL Endotoxin Assay Platform

EAST FALMOUTH, Mass. and SUNNYVALE, Calif., July 8 /PRNewswire/ -- Associates of Cape Cod, Inc. (ACC) and MDS Analytical Technologies are pleased to announce the launch of ACC's Chromogenic LAL Endotoxin assay kits utilizing MDS Analytical Technologies' SpectraMax(R) instrument platform and SoftMax(R) Pro GxP software.

ACC and MDS Analytical Technologies collaborated on an FDA 21 CFR part 11 solution for ACC's Chromogenic LAL Endotoxin assay kits. The partnership was based on ACC's validation of MDS Analytical Technologies' VersaMax(TM) monochromator-based absorbance microplate reader using the SoftMax(R) Pro GxP software compliant environment.

ACC offers several chromogenic assays: Pyrochrome(R) and Chromo-LAL for endotoxin detection and Glucatell(R) to detect (1,3)-beta-D-glucan in industrial applications. All methods are optimized for use in microplate detection systems such as the VersaMax(TM) reader.

SoftMax(R) Pro 5 GxP software from MDS Analytical Technologies is the industry standard microplate analysis software, offering extensive data capture and analysis capabilities in a FDA 21 CFR Part 11 compliant environment for MDS Analytical Technologies' SpectraMax(R) line of microplate readers. It includes features that make it particularly well suited to endotoxin and glucan assays.

"We are proud to partner with one of the world's largest manufacturers of assay kits to detect endotoxin in drugs and biological products," said Andy Boorn, President of MDS Analytical Technologies. "Our pharmaceutical and biotechnology customers performing tests on the SpectraMax instrument platform can now increase their capital asset utilization by running LAL assays on SpectraMax readers. In addition, they can leverage the FDA 21 CFR Part 11 compliant system setup with SoftMax Pro GxP software reducing additional compliance costs required with third-party vendor solutions."

ACC President & CEO A.J. Meuse, Ph.D. added, "Partnering with MDS Analytical Technologies, one of the premier bioanalytical instrument companies in the world, further strengthens our ability to meet the variety of instrument and software requirements our customers have for endotoxin and (1,3)-beta-D-glucan analysis. We are pleased to offer our customers the VersaMax(TM) plate reader which provides additional functionality for product release testing in an FDA 21 CFR Part 11 compliant environment."

Customized assay methods for Chromo-LAL, Glucatell(R), Glucatell(R) Diazo, Pyrochrome(R), Pyrochrome(R) Diazo assay kits are available for SoftMax(R) Pro software version 5.2 GxP and greater.

About Associates of Cape Cod, Inc.

Associates of Cape Cod, Inc., based in East Falmouth, MA, is a leader in the field of bacterial endotoxin and beta-glucan detection and a major supplier to the pharmaceutical, medical device and clinical diagnostic industries. A wholly owned subsidiary of Seikagaku BioBusiness Corporation, the Company pioneered the humane use of the horseshoe crab blood extract, Limulus Amebocyte Lysate (LAL), used in the testing of pharmaceuticals, medical devices and biologics, for the presence of potentially toxic endotoxins and glucans. Our products are marketed throughout the world under the trade names Pyrotell(R), Glucatell(R), Pyrochrome(R) and Chromo-LAL. The Company offers contract testing for endotoxins and glucans, and has a research biochemical's division, Northstar BioProducts(TM), specializing in carbohydrate chemistry. The Company also produces a clinical diagnostic test, Fungitell(R), for use by physicians to aid in the diagnosis of invasive fungal infections, and runs the CLIA approved Beacon Diagnostics(R) Laboratory for patient sample analysis. For more information about Associates of Cape Cod, Inc. and our products, please visit our websites at: or or call us at 1-888-395-2221.

About MDS Analytical Technologies

MDS Analytical Technologies is a newly established unit of MDS Inc. and is comprised of two main lines of business. The Sciex product portfolio offers proven market leadership in mass spectrometry. The Molecular Devices product portfolio is the gold standard in high-performance bioanalytical measurement systems that accelerate and improve drug discovery and other life sciences research. Find out more at or

VERSAMAX is a trademark of MDS Analytical Technologies (US) Inc., and SPECTRAMAX and SOFTMAX are registered trademarks of MDS Analytical Technologies (US) Inc.

Contact Info:

For further information contact:


Cheri Salazar

Director, Global Marketing Communications

Molecular Devices, now part of MDS Analytical Technologies

(408) 548-6316

SOURCE Associates of Cape Cod, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Sign Language Associates and Visual Language Interpreting Combine With GoAmerica to Form Nations Premier Sign Language Interpreting Services Company
2. Jack Henry & Associates Divests Insurance Agency Outsourcing Business Line
3. J.D. Power and Associates Reports: A Vast Majority of Southern California Indian Gaming Casino Customers Express Desire for a Smoke-Free Environment
4. Parks Associates Analysts Present Insights on Broadband, Digital Content, Advertising, Home Systems, and Digital Health at CONNECTIONS(TM)
5. Foundation Radiology Group and Cherry Tree Medical Associates Sign Multi-Year Contract for Diagnostic Services
6. Blue Cross and Blue Shield of Florida Awarded Prestigious J.D. Power and Associates Award for Second Year
7. Booth Radiology Associates Chooses IDC To Complete Its Transition To Digital Imaging
8. Charterhouse Group Partners with MTS Health Investors and Highlander Partners to Acquire Chamberlin Edmonds & Associates, Inc., a Leading Provider of Eligibility Services to Hospitals
9. J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers
10. Berkery Noyes Represents Princeton Media Associates in Its Sale to HMP Communications/Alta
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on BioCurex, Inc.
Post Your Comments:
(Date:11/25/2015)... ... ... “While riding the bus, I saw a passenger in a wheelchair drenched from ... a convenient and comfortable way to protect them from bad weather, so I invented ... during cold or inclement weather. In doing so, it ensures that the user remains ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
(Date:11/25/2015)... ... November 25, 2015 , ... An unlikely combination ... in a way for homeless people to have a more dignified and comfortable ... initiative whereby they are repurposing plastic bags into sleeping mats for the homeless. ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... focused on providing comprehensive solutions involving adult stem cell therapies to patients with ... deemed the “Regenestem” name as a Registered Trademark (RTM). , Organizations are required ...
(Date:11/24/2015)... ... 2015 , ... Genesis Chiropractic Software helps practice owners automate ... between the practice owner and the patient that automatically manages all five aspects ... Click here to learn more. , According to Dr. Brian ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , November 25, 2015 Kitov ... ) (TASE: KTOV), a biopharmaceutical company focused on the ... various clinical conditions, today announced the closing of its ... Shares ( ADSs ), each representing 20 ordinary shares ... 3,158,900 ADSs. The ADSs and warrants were issued in ...
(Date:11/25/2015)... , Nov. 25, 2015 Allergan ... pharmaceutical company, and Rugen Therapeutics, a start-up  biotechnology ... for unmet CNS disorders and funded by the ... they have entered into an exclusive collaboration to ... for Autism Spectrum Disorders (ASD) and Obsessive Compulsive ...
(Date:11/25/2015)... Israel , November 25, 2015 ... "New Investors"), pursuant to which BioLight and the New ... IOPtima Ltd. subsidiary ("IOPtima") via a private placement. The ... of its innovative IOPtimate™ system used in the treatment ... approval pathway process for the IOPtimate™ system with the ...
Breaking Medicine Technology: